These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34789416)

  • 21. Characteristics of the 24-h ambulatory blood pressure monitoring in patients with Parkinson's disease - the SFC BP multicentre study in China.
    Chen SW; Wang YK; Dou RH; Xie XY; Hu YB; Ding N; Zhang GH; Jing HF; Zhao WD; Xue Y; Li Y; Wang G
    J Hypertens; 2020 Nov; 38(11):2270-2278. PubMed ID: 32649630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential significance of hepcidin evaluation in progressive supranuclear palsy.
    Alster P; Otto-Ślusarczyk D; Wiercińska-Drapało A; Struga M; Madetko-Alster N
    Brain Behav; 2024 Jun; 14(6):e3552. PubMed ID: 38953731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pattern of verbal, visuospatial and procedural learning in Richardson variant of progressive supranuclear palsy in comparison to Parkinson's disease.
    Sitek EJ; Wieczorek D; Konkel A; Dąbrowska M; Sławek J
    Psychiatr Pol; 2017 Aug; 51(4):647-659. PubMed ID: 28987055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants.
    Street D; Malpetti M; Rittman T; Ghosh BCP; Murley AG; Coyle-Gilchrist I; Passamonti L; Rowe JB
    Brain Commun; 2021; 3(3):fcab206. PubMed ID: 34541533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SCOPA-AUT scale in different parkinsonisms and its correlation with (123) I-MIBG cardiac scintigraphy.
    Berganzo K; Tijero B; Somme JH; Llorens V; Sánchez-Manso JC; Low D; Iodice V; Vichayanrat E; Mathias CJ; Lezcano E; Zarranz JJ; Gómez-Esteban JC
    Parkinsonism Relat Disord; 2012 Jan; 18(1):45-8. PubMed ID: 21908227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Instability of syllable repetition in progressive supranuclear palsy.
    Skodda S; Grönheit W; Schlegel U
    J Neural Transm (Vienna); 2012 Apr; 119(4):457-62. PubMed ID: 22065210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study.
    Nigro S; Antonini A; Vaillancourt DE; Seppi K; Ceravolo R; Strafella AP; Augimeri A; Quattrone A; Morelli M; Weis L; Fiorenzato E; Biundo R; Burciu RG; Krismer F; McFarland NR; Mueller C; Gizewski ER; Cosottini M; Del Prete E; Mazzucchi S; Quattrone A
    Mov Disord; 2020 Jun; 35(6):976-983. PubMed ID: 32092195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative evaluation of oculomotor disturbances in progressive supranuclear palsy.
    Pagonabarraga J; Horta-Barba A; Busteed L; Bejr-Kasem H; Illán-Gala I; Aracil-Bolaños I; Marín-Lahoz J; Pascual-Sedano B; Pérez J; Campolongo A; Izquierdo C; Martinez-Horta S; Sampedro F; Kulisevsky J
    Parkinsonism Relat Disord; 2021 Apr; 85():63-68. PubMed ID: 33744691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The applause sign and neuropsychological profile in progressive supranuclear palsy and Parkinson's disease.
    Somme J; Gómez-Esteban JC; Tijero B; Berganzo K; Lezcano E; Zarranz JJ
    Clin Neurol Neurosurg; 2013 Aug; 115(8):1230-3. PubMed ID: 23253819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy.
    Seki M; Seppi K; Mueller C; Potrusil T; Goebel G; Reiter E; Nocker M; Steiger R; Wildauer M; Gizewski ER; Wenning GK; Poewe W; Scherfler C
    Parkinsonism Relat Disord; 2018 Apr; 49():81-87. PubMed ID: 29463454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vestibular symptoms as the presenting feature of progressive supranuclear palsy.
    Haggstrom L; Brew B; Sutton I; Tisch S
    J Clin Neurosci; 2018 Apr; 50():74-76. PubMed ID: 29398194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes.
    Horta-Barba A; Pagonabarraga J; Martínez-Horta S; Busteed L; Pascual-Sedano B; Illán-Gala I; Marin-Lahoz J; Aracil-Bolaños I; Pérez-Pérez J; Sampedro F; Bejr-Kasem H; Kulisevsky J
    J Neurol; 2021 Sep; 268(9):3400-3408. PubMed ID: 33704556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Progressive Supranuclear Palsy Rating Scale with Progressive Supranuclear Palsy Quality of Life Scale.
    Pantelyat A; Higginbotham L; Rosenthal L; Lanham D; Nesspor V; AlSalihi M; Bang J; Wang J; Albert M
    Neurodegener Dis; 2020; 20(4):139-146. PubMed ID: 33789283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.
    Fiorenzato E; Weis L; Falup-Pecurariu C; Diaconu S; Siri C; Reali E; Pezzoli G; Bisiacchi P; Antonini A; Biundo R
    J Neural Transm (Vienna); 2016 Dec; 123(12):1435-1442. PubMed ID: 27334897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rate of decline in progressive supranuclear palsy.
    Litvan I; Kong M
    Mov Disord; 2014 Apr; 29(4):463-8. PubMed ID: 24615741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can the frontal assessment battery (FAB) differentiate bradykinetic rigid syndromes? Relation of the FAB to formal neuropsychological testing.
    Paviour DC; Winterburn D; Simmonds S; Burgess G; Wilkinson L; Fox NC; Lees AJ; Jahanshahi M
    Neurocase; 2005 Aug; 11(4):274-82. PubMed ID: 16093228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease.
    Ling H; Massey LA; Lees AJ; Brown P; Day BL
    Brain; 2012 Apr; 135(Pt 4):1141-53. PubMed ID: 22396397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gait Analysis in Progressive Supranuclear Palsy Phenotypes.
    Picillo M; Ricciardi C; Tepedino MF; Abate F; Cuoco S; Carotenuto I; Erro R; Ricciardelli G; Russo M; Cesarelli M; Barone P; Amboni M
    Front Neurol; 2021; 12():674495. PubMed ID: 34177779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Utility of Tectal Plate Measurements on Magnetic Resonance Imaging in Progressive Supranuclear Palsy.
    Amrami A; Singh NA; Ali F; Pham NTT; Stephens YC; Josephs KA; Whitwell JL
    Mov Disord; 2024 Aug; 39(8):1402-1407. PubMed ID: 38586905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological Status.
    Duff K; McDermott D; Luong D; Randolph C; Boxer AL
    J Clin Exp Neuropsychol; 2019 Jul; 41(5):469-475. PubMed ID: 30712468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.